Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
New Nasal Spray to Treat Depression Gets FDA Approval
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Nose spray to treat depression? FDA approves first-of-its-kind medicine
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
FDA approves first nasal spray treatment for severe depression
The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe ...
FDA approves standalone use of J&J's ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
FDA approves J&J’s nasal spray for severe depression as stand-alone treatment
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
mic9h
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Pharm Exec1d
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).